|Bid||11.04 x 2200|
|Ask||11.05 x 3200|
|Day's Range||10.97 - 11.71|
|52 Week Range||9.58 - 36.35|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||18.25|
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. NASDAQ and Russell 2000 indices were already in correction territory. More importantly, Russell 2000 ETF (IWM) underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points in the fourth quarter. Hedge funds and institutional […]
Acorda Therapeutics Inc NASDAQ/NGS:ACORView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderately high for ACOR with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding ACOR are favorable, with net inflows of $3.56 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...
Acorda (ACOR) delivered earnings and revenue surprises of 42.27% and 20.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Ardsley, New York-based company said it had a loss of $1 per share. Losses, adjusted for non-recurring costs and stock option expense, came to 56 cents per share. The results topped Wall Street expectations. ...
ARDSLEY, N.Y.-- -- INBRIJA™ commercially available on February 28; first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa INBRIJA 1Q 2019 net sales of $1.3 million; approximately 2,000 prescription request forms received through April 2019 AMPYRA ® 1Q 2019 net sales of $40.1 million Acorda Therapeutics, Inc. provided ...
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
If you're interested in Acorda Therapeutics, Inc. (NASDAQ:ACOR), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. Volatility is conside...
Acorda Therapeutics, Inc. (ACOR) will host a conference call and webcast to report its first quarter 2019 update and financial results on Thursday, May 2 at 8:30 a.m. ET. The archived webcast will be available in the Investor Relations section of the Acorda website at www.acorda.com. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.
Acorda (ACOR) aims to boost sales with the launch of its newly FDA-approved Parkinson's disease drug, Inbrija. The company's pipeline looks promising as well.
Acorda Therapeutics, Inc. (ACOR) will present three posters with Phase 3 data on INBRIJA at the upcoming Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting taking place March 25-28, 2019, in San Diego. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment of OFF episodes in people with Parkinson’s taking carbidopa/levodopa.
Acorda (ACOR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In the latest trading session, Acorda Therapeutics (ACOR) closed at $14.62, marking a +0.14% move from the previous day.
One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will work through how we can use ReturnRead More...
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Andrew Hindman, Chief Business Officer, will transition out of the Company over the coming months. “We thank Andrew for his many contributions to Acorda over the past five years. One of his first achievements was helping to lead Acorda’s acquisition of Civitas and INBRIJA, which was transformational for the Company,” said Ron Cohen, M.D., Acorda’s President and CEO.
Acorda Therapeutics, Inc. (ACOR) announced that Andrew Hindman, Acorda’s Chief Business Officer, will present at the Oppenheimer & Co. Annual Healthcare Conference on Tuesday, March 19 at 1:35 p.m. EST. Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders. INBRIJA™ (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa.
LOS ANGELES, March 05, 2019 -- Glancy Prongay & Murray LLP (“GPM”) announces its investigation on behalf of Acorda Therapeutics, Inc. (NASDAQ: ACOR) investors concerning.
NEW YORK, March 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that INBRIJA is now available by prescription in the United States. INBRIJA was approved by the U.S. Food and Drug Administration (FDA) on December 21, 2018 for intermittent treatment in people with Parkinson’s taking carbidopa/levodopa who experience OFF episodes. “OFF periods are extremely disruptive for those living with Parkinson’s. We are excited that INBRIJA is now available to address this important unmet medical need, and that prescriptions are already being filled,” said Ron Cohen, M.D., Acorda’s President and CEO.